• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.一组在携带ROS1基因重排的转移性非小细胞肺癌患者中使用含培美曲塞治疗实现长期无进展生存的病例系列。
Clin Lung Cancer. 2013 Sep;14(5):592-5. doi: 10.1016/j.cllc.2013.04.008. Epub 2013 Jun 27.
2
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.ROS1 重排对从不吸烟的肺腺癌患者临床结局的频率和影响。
Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.
3
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.非小细胞肺癌中间变性淋巴瘤激酶基因重排与培美曲塞治疗后的无进展生存期延长相关。
J Thorac Oncol. 2011 Apr;6(4):774-80. doi: 10.1097/JTO.0b013e31820cf053.
4
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.培美曲塞为基础的化疗在 ROS1 融合阳性肺腺癌患者中的疗效与东亚人群中携带其他驱动基因突变患者的疗效比较。
J Thorac Oncol. 2016 Jul;11(7):1140-52. doi: 10.1016/j.jtho.2016.03.022. Epub 2016 Apr 16.
5
Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.ROS1重排阳性的非小细胞肺癌患者可从培美曲塞化疗中获益。
Cancer Med. 2016 Oct;5(10):2688-2693. doi: 10.1002/cam4.809. Epub 2016 Aug 20.
6
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.ROS1 重排非小细胞肺癌患者中不同类型 ROS1 融合伙伴的克唑替尼疗效。
J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25.
7
Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.克唑替尼和培美曲塞化疗方案对中国ROS1重排非小细胞肺癌患者的疗效
Oncotarget. 2016 Nov 15;7(46):75145-75154. doi: 10.18632/oncotarget.12612.
8
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.驱动癌基因与非小细胞肺癌患者培美曲塞长期疗效的关系
Clin Lung Cancer. 2015 Sep;16(5):366-73. doi: 10.1016/j.cllc.2014.12.009. Epub 2014 Dec 31.
9
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.克唑替尼治疗后进展的 ROS1 重排非小细胞肺癌患者的治疗模式和临床结局。
Clin Lung Cancer. 2020 Sep;21(5):e478-e487. doi: 10.1016/j.cllc.2020.03.008. Epub 2020 Apr 15.
10
First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.一线克唑替尼与铂类培美曲塞化疗用于晚期 ROS1 重排非小细胞肺癌患者。
Cancer Med. 2020 May;9(10):3310-3318. doi: 10.1002/cam4.2972. Epub 2020 Mar 13.

引用本文的文献

1
Disease control in patients with non-small cell lung cancer using pemetrexed: Investigating the best treatment strategy.培美曲塞用于非小细胞肺癌患者的疾病控制：探寻最佳治疗策略。
Thorac Cancer. 2024 Apr;15(12):987-993. doi: 10.1111/1759-7714.15286. Epub 2024 Mar 14.
2
A case of CD74-ROS1-positive lung adenocarcinoma diagnosed by next-generation sequencing achieved long-term survival with pemetrexed regimens.一例经下一代测序诊断为 CD74-ROS1 阳性肺腺癌患者，使用培美曲塞方案治疗后获得长期生存。
Thorac Cancer. 2023 Sep;14(25):2618-2621. doi: 10.1111/1759-7714.15041. Epub 2023 Jul 24.
3
Deepening the Knowledge of Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.深入了解非小细胞肺癌中的重排：诊断、治疗、耐药和伴随改变。
Int J Mol Sci. 2021 Nov 28;22(23):12867. doi: 10.3390/ijms222312867.
4
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.聚焦ROS1阳性非小细胞肺癌（NSCLC）：克唑替尼、耐药机制及新一代靶向治疗
Cancers (Basel). 2020 Nov 6;12(11):3293. doi: 10.3390/cancers12113293.
5
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.克唑替尼与铂类化疗作为不同 ROS1 融合变异晚期非小细胞肺癌的一线治疗。
Cancer Med. 2020 May;9(10):3328-3336. doi: 10.1002/cam4.2984. Epub 2020 Mar 13.
6
First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.一线克唑替尼与铂类培美曲塞化疗用于晚期 ROS1 重排非小细胞肺癌患者。
Cancer Med. 2020 May;9(10):3310-3318. doi: 10.1002/cam4.2972. Epub 2020 Mar 13.
7
Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.晚期肺腺癌 EZR-ROS1 重排患者的长期无进展生存：病例报告。
BMC Pulm Med. 2018 Jan 23;18(1):13. doi: 10.1186/s12890-018-0585-9.
8
Recent Advances in Targeting ROS1 in Lung Cancer.ROS1 靶向治疗肺癌的最新进展。
J Thorac Oncol. 2017 Nov;12(11):1611-1625. doi: 10.1016/j.jtho.2017.08.002. Epub 2017 Aug 14.
9
AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?AURA 3研究：化疗作为EGFR突变型非小细胞肺癌对照臂的最终定论？
Ann Transl Med. 2017 May;5(Suppl 1):S14. doi: 10.21037/atm.2017.03.73.
10
Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.克唑替尼和培美曲塞化疗方案对中国ROS1重排非小细胞肺癌患者的疗效
Oncotarget. 2016 Nov 15;7(46):75145-75154. doi: 10.18632/oncotarget.12612.

本文引用的文献

1
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.鉴定和靶向非小细胞肺癌中的 ROS1 基因融合。
Clin Cancer Res. 2012 Sep 1;18(17):4570-9. doi: 10.1158/1078-0432.CCR-12-0550. Epub 2012 Aug 23.
2
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.培美曲塞为基础的化疗用于晚期 ALK 阳性非小细胞肺癌患者。
Ann Oncol. 2013 Jan;24(1):59-66. doi: 10.1093/annonc/mds242. Epub 2012 Aug 10.
3
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.培美曲塞联合最佳支持治疗维持治疗对比安慰剂联合最佳支持治疗用于培美曲塞联合顺铂诱导治疗后的晚期非鳞状非小细胞肺癌（PARAMOUNT）：一项双盲、III 期、随机对照临床试验。
Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16.
4
ROS1 rearrangements define a unique molecular class of lung cancers.ROS1 重排定义了一类独特的肺癌分子亚型。
J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.
5
Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.间变性淋巴瘤激酶易位：预测培美曲塞在非小细胞肺癌患者中的疗效的生物标志物。
J Thorac Oncol. 2011 Sep;6(9):1474-80. doi: 10.1097/JTO.0b013e3182208fc2.
6
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.非小细胞肺癌中间变性淋巴瘤激酶基因重排与培美曲塞治疗后的无进展生存期延长相关。
J Thorac Oncol. 2011 Apr;6(4):774-80. doi: 10.1097/JTO.0b013e31820cf053.
7
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.培美曲塞根据非小细胞肺癌组织学类型的疗效差异：两项III期研究的综述
Oncologist. 2009 Mar;14(3):253-63. doi: 10.1634/theoncologist.2008-0232. Epub 2009 Feb 16.
8
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.一项III期研究，比较顺铂加吉西他滨与顺铂加培美曲塞用于初治晚期非小细胞肺癌患者的化疗效果。
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
9
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.磷酸酪氨酸信号的全球调查确定了肺癌中的致癌激酶。
Cell. 2007 Dec 14;131(6):1190-203. doi: 10.1016/j.cell.2007.11.025.
10
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.培美曲塞与多西他赛用于既往接受过化疗的非小细胞肺癌患者的随机III期试验。
J Clin Oncol. 2004 May 1;22(9):1589-97. doi: 10.1200/JCO.2004.08.163.

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

作者信息

Riess Jonathan W, Padda Sukhmani K, Bangs Charles D, Das Millie, Neal Joel W, Adrouny Adour R, Cherry Athena, Wakelee Heather A

机构信息

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Clin Lung Cancer. 2013 Sep;14(5):592-5. doi: 10.1016/j.cllc.2013.04.008. Epub 2013 Jun 27.

DOI:10.1016/j.cllc.2013.04.008
PMID:23810364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4156821/
Abstract
摘要